2. Search Result
Search Result
Results for "

glucose concentration

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

2

Peptides

3

Natural
Products

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109500
    Masoprocol

    meso-Nordihydroguaiaretic acid; meso-NDGA

    		 Lipoxygenase Metabolic Disease Cancer
    Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .
    Masoprocol
  • HY-109018A
    Velagliflozin proline
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline
  • HY-109018B
    Velagliflozin proline hydrate
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline hydrate
  • HY-109500R
    Masoprocol (Standard)

    		Lipoxygenase Metabolic Disease Cancer
    Masoprocol (Standard) is the analytical standard of Masoprocol. This product is intended for research and analytical applications. Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .
    Masoprocol (Standard)
  • HY-158639
    12-POHSA

    		Endogenous Metabolite Metabolic Disease
    12-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 12-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .
    12-POHSA
  • HY-158584
    13-OAHSA

    9Z-Octadecenoic acid, 12-carboxy-1-pentyldodecyl ester

    		 Endogenous Metabolite Metabolic Disease
    13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .
    13-OAHSA
  • HY-158583
    13-POHSA

    		Endogenous Metabolite Metabolic Disease
    13-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .
    13-POHSA
  • HY-148247
    BI-2081

    		Free Fatty Acid Receptor Metabolic Disease
    BI-2081 is a GPR40 (FFAR1) partial agonist (EC50: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2 .
    BI-2081
  • HY-118113
    BVT-116429

    		11β-HSD Others
    BVT-116429 is an 11βHSD1 inhibitor with the activity of increasing adiponectin concentration and improving glucose homeostasis in diabetic mice. BVT-116429 can increase plasma adiponectin levels in diabetic KKAy mice, reduce basal insulin levels, and reduce fasting blood glucose levels after 10 days of inhibition, similar to the effect of rosiglitazone.
    BVT-116429
  • HY-158650
    10-OAHSA

    		Endogenous Metabolite TNF Receptor Inflammation/Immunology Endocrinology
    10-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 10-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration. 10-OAHSA reduces LPS (HY-D1056)-induced Tnf-α secretion in bone marrow-derived dendritic cells (BMDCs) .
    10-OAHSA
  • HY-P3621
    Biotinyl-Glucagon (1-29), human, bovine, porcine

    		GCGR Metabolic Disease
    Biotinyl-Glucagon (1-29), human, bovine, porcine is a biotinylated glucagon. Glucagon is a peptide hormone, produced by α-cells of the pancreas, can increase concentration of glucose and fatty acids in the bloodstream .
    Biotinyl-Glucagon (1-29), human, bovine, porcine
  • HY-170572
    PB01

    		Dipeptidyl Peptidase Reactive Oxygen Species (ROS) Metabolic Disease
    PB01 is a DPP-4 inhibitor with an IC50 of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes .
    PB01
  • HY-155034
    Antitumor agent-102

    		Topoisomerase GLUT Cancer
    Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .
    Antitumor agent-102
  • HY-P2979A
    Invertase, candida sp.

    β-D-Fructofuranosidase, candida sp.

    		 Biochemical Assay Reagents Others
    Invertase from Candida sp. is responsible for catalyzing the hydrolysis of sucrose into glucose and fructose and is widely used in the field of carbohydrate processing. Invertase from Candida sp. can be used for enzymatic determination of sucrose concentration as well as for structural analysis of carbohydrates containing β-D-fructofuranosyl residues .
    Invertase, candida sp.
  • HY-123765
    JTT-553

    		Acyltransferase Metabolic Disease
    JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .
    JTT-553
  • HY-125327
    YM-543

    		SGLT Metabolic Disease
    YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.
    YM-543
  • HY-139792
    Besigliptin tosylate

    SHR117887

    		 Endogenous Metabolite Metabolic Disease
    Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
    Besigliptin tosylate
  • HY-19824
    3PO
    Maximum Cited Publications
    23 Publications Verification

    		 Autophagy Cancer
    3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD + and NADH. 3PO can be used for the research of cancer .
    3PO
  • HY-108615
    CP-316819

    GPi 819

    		 Phosphorylase Endocrinology
    CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents .
    CP-316819
  • HY-P3954
    Somatostatin-28 (sheep, human rat mouse)

    		Somatostatin Receptor Metabolic Disease
    Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .
    Somatostatin-28 (sheep, human rat mouse)
  • HY-113513
    5-HEPE

    		Others Cancer
    5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
    5-HEPE
  • HY-168495
    α-Amylase-IN-12

    		Amylases Glycosidase Metabolic Disease
    α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor (IC50: 0.15 mM) with a mixed inhibition. α-Amylase-IN-12 has an IC50 of 9.40 mM against α-glucosidase. α-Amylase-IN-12 promotes glucose uptake in yeast cells and exhibits significant antiglycation activity at high concentrations. α-Amylase-IN-12 can be used for the research of diabetes .
    α-Amylase-IN-12
  • HY-B1876
    Nicosulfuron

    		Acetolactate Synthase (ALS) Photosystem II Fungal Others
    Nicosulfuron is efficient, harmless, antifungal and selective herbicide belonging to the sulfonylurea family. Nicosulfuron is also a photosynthetic system inhibitor and inhibits acetolactate synthase (ALS) enzyme activity. Nicosulfuron degradation by Plectosphaerella cucumerina AR1 is glucose concentration dependent in planktonic lifestyle. Nicosulfuron enhances the glycolysis pathway and tricarboxylic acid cycle to improve the adaptability of sweet maize. Nicosulfuron reduces the synthesis of branched-chain amino acids (BCAAs), which is proming for maize cultivation .
    Nicosulfuron
  • HY-I0786
    (2S,4R)-Teneligliptin

    		Dipeptidyl Peptidase Metabolic Disease
    (2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). (2S,4R)-Teneligliptin increases the plasma concentration of active glucagon-like peptide-1 (GLP-1), which promotes insulin secretion in response to elevated blood glucose levels, exerting hypoglycemic activity. (2S,4R)-Teneligliptin is promising for research of type 2 diabetes .
    (2S,4R)-Teneligliptin
  • HY-151486
    GLUT1-IN-1

    		GLUT Cancer
    GLUT1-IN-1 is a glucose transporter 1 (GLUT1) inhibitor and has a GLUT1-specific inactivation ability. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer .
    GLUT1-IN-1
  • HY-170796
    α-Amylase-IN-11

    		Amylases Metabolic Disease
    α-Amylase-IN-11 (compound C5f) is an α-Amylase inhibitor (IC50=0.56 μM) that can reduce the sugar level in vivo. α-Amylase-IN-11 has a moderate inhibitory effect on α-glucosidase (α-glucosidase), with IC50=11.03 μM. α-Amylase-IN-11 can significantly reduce the glucose concentration in a mouse model and has the potential for use in diabetes research .
    α-Amylase-IN-11
  • HY-124399
    N-Octadecyl-N'-propyl-sulfamide

    		Endogenous Metabolite PPAR Metabolic Disease
    Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.
    N-Octadecyl-N'-propyl-sulfamide
  • HY-112624B
    Dextran T70 (MW 70,000)

    Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)

    		 Bacterial Others
    Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
    Dextran T70 (MW 70,000)
  • HY-112624H
    Dextran T2 (MW 2,000)

    Dextran 2; Dextran D2; Dextran T2(MW 1600-2400)

    		 Biochemical Assay Reagents Others
    Dextran T2 (Dextran 2; Dextran T2(MW 1600-2400)) is a natural high molecular weight polysaccharide, the glycosidic bonds in its structure can be recognized by endo-dextranase and exo-dextranase. Dextran T2 (MW 2,000) breaks the glycosidic bonds in the enzymatic hydrolysis mechanism, releasing products such as D-glucose, Isomaltose (IM2), and Isomaltotriose (IM3). Dextran T2 (MW 2,000) can be used as a model substrate to characterize the catalytic properties of dextranase (such as optimal pH, temperature and product specificity), and to study enzymatic mechanism research and polysaccharide degradation pathways in glycobiology. The Dextran series of compounds are also a natural polysaccharide drug carrier, which can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity .
    Dextran T2 (MW 2,000)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: